benzonidazole (benznidazole)

01/01/2018 - "Chagas disease, caused by Trypanosoma cruzi, is an important global public health problem which, despite partial efficacy of benznidazole (Bz) in acute phase, urgently needs an effective treatment. "
06/01/2011 - "We have tested the antiparasital activity in vitro and in vivo of the three new complexes against Trypanosoma cruzi showing very promising results and overcoming clearly the reference drug commonly used for the Chagas disease treatment, benznidazole."
08/25/2021 - "Benznidazole, the only drug approved for treatment, effectively treats acute-stage Chagas disease, but its effectiveness for treating indeterminate and chronic stages remains uncertain. "
03/01/2016 - "Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. "
07/01/2008 - "Benznidazole is effective for treating acute and chronic (recently acquired) Trypanosoma cruzi infection (Chagas' disease). "

01/01/2020 - "Treatment of infants with benznidazole is highly efficacious in eliminating infection. "
01/01/2018 - "Treatment of infants with benznidazole is highly efficacious in eliminating infection. "
01/01/2020 - "Because the disease can manifest itself clinically a few years to decades after infection, controversy remains concerning the suitability of current drug treatment (benznidazole), and the efficacy of alternative drugs (e.g. "
02/01/2013 - "Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi."
01/01/2022 - "This study evaluates the efficacy of MLT as a monodrug and combined with benznidazole (BZ) in both in vitro and in vivo models of infection with T. "

01/01/2017 - "There was a significant reduction in the number of treatment days (number of doses) necessary to induce parasitemia suppression with all four compounds compared to that required with benznidazole. "
09/01/2005 - "The patient was put on benznidazole with rapid clearance of the parasitemia. "
11/01/1998 - "Treatment with benznidazole was effective in reducing parasitemia, stabilizing the clinical status, and controlling tissue damage related to the parasite. "
01/01/1998 - "Specific antitrypanosomal treatment with benznidazole was effective in reducing the level of parasitemia and improving the clinical condition in three of the four patients treated."
12/01/2016 - "The in vivo study found a reduction of parasitemia in animals treated with TDZ 2 alone or combined with benznidazole. "

10/01/2012 - "There was a significant reduction of inflammation in skeletal muscles after benznidazole treatment in animals infected with Mexican T. "
01/01/2017 - "The clinical efficacy of benznidazole could be improved by decreasing chronic inflammation. "
07/16/2018 - "Inflammation of heart vessels from Cur-treated and untreated infected mice were analysed by histology, with benznidazole (Bz) as the reference compound. "
10/01/2012 - "We analyzed the intensity of inflammation and parasitism in BALB/c mice infected with Trypanosoma cruzi I stocks from Mexico with and without benznidazole treatment in the acute phase of disease. "
10/01/2012 - "Decreased intensity of inflammation in benznidazole-treated mice inoculated with Trypanosoma cruzi I stocks from Mexico and persistence of circulating parasites."

08/01/2010 - "The results of the Benznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT) trial in 2012 will also help to inform treatment. "
10/01/2014 - "cruzi, and developed cerebral trypanosomiasis that was successfully treated with benznidazole at 7 mg/kg/day for 60 days. "
03/01/2017 - "Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial."
01/01/2013 - "The Benznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) study is an international, multicenter, randomized, double-blinded and placebo-controlled clinical trial to evaluate the efficacy of benznidazole (BZ) treatment in patients with chronic Chagas cardiomyopathy (CCC). "
07/01/2009 - "The BENEFIT project--Benznidazole Evaluation for Interrupting Trypanosomiasis--is an international, multicenter, double-blind, placebo-controlled trial of trypanocidal treatment with benznidazole in patients with chronic Chagas heart disease. "